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Abstract
Background: For over a decade, the importance of zinc in the treatment of acute and persistent diarrhea has been
recognized. In spite of recently published reviews, there remain several unanswered questions about the role of zinc
supplementation in childhood diarrhea in the developing countries. Our study aimed to assess the therapeutic benefits of
zinc supplementation in the treatment of acute or persistent diarrhea in children, and to examine the causes of any
heterogeneity of response to zinc supplementation.
Methods and Findings: EMBASEH, MEDLINE H and CINAHLH databases were searched for published reviews and meta-
analyses on the use of zinc supplementation for the prevention and treatment of childhood diarrhea. Additional RCTs
published following the meta-analyses were also sought. The reviews and published RCTs were qualitatively mapped
followed by updated random-effects meta-analyses, subgroup meta-analyses and meta-regression to quantify and
characterize the role of zinc supplementation with diarrhea-related outcomes. We found that although there was evidence
to support the use of zinc to treat diarrhea in children, there was significant unexplained heterogeneity across the studies
for the effect of zinc supplementation in reducing important diarrhea outcomes. Zinc supplementation reduced the mean
duration of diarrhea by 19.7% but had no effect on stool frequency or stool output, and increased the risk of vomiting. Our
subgroup meta-analyses and meta-regression showed that age, stunting, breast-feeding and baseline zinc levels could not
explain the heterogeneity associated with differential reduction in the mean diarrheal duration. However, the baseline zinc
levels may not be representative of the existing zinc deficiency state.
Conclusions: Understanding the predictors of zinc efficacy including the role of diarrheal disease etiology on the response
to zinc would help to identify the populations most likely to benefit from supplementation. To improve the programmatic
use of zinc, further evaluations of the zinc salts used, the dose, the frequency and duration of supplementation, and its
acceptability are required. The significant heterogeneity of responses to zinc suggests the need to revisit the strategy of
universal zinc supplementation in the treatment children with acute diarrhea in developing countries.
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Introduction
Despite significant improvements in the interventions to treat
diarrhea in children, it continues to pose a daunting public health
challenge, especially in children from developing countries. Recent
estimates suggest that nearly 3% of neonatal mortality and 17% of
under-five child mortality is attributable to diarrhea. Asia and
Africa have an alarmingly high incidence of childhood diarrhea.
[1,2,3] Although the burden of the diarrhea-related mortality has
significantly decreased since the introduction of oral rehydration
therapy in 1980, diarrheal diseases in children remain a substantial
global health problem. [4,5,6] In 2004, the World Health
Organization (WHO) and the United Nations Children’s Fund
(UNICEF) took two significant steps to reduce this burden by
recommending the use of low-osmolarity oral rehydration solution
(ORS), and supplementation with zinc for up to two weeks as part
of the case management of acute diarrhea. [7,8]
The latter recommendation was based on the results of several
randomized controlled trials, meta-analyses [9] and reviews
[10,11,12,13] reported from around the world that have
demonstrated the utility of zinc supplementation to shorten the
duration of diarrhea and improve other diarrhea related
outcomes. Nearly five years have elapsed and substantial
additional evidence [14,15,16,17,18,19] has accumulated since
the inception of the practice of zinc supplementation. The existing
paradigm strongly supports the notion of zinc supplementation;
however, recent scientific reports suggest several interesting cues
described below indicate that a more focused approach to zinc
supplementation may be required.
First, WHO/UNICEF recommends zinc supplementation for
diarrhea in developing countries only. [19] The underlying
justification for this is the differential prevalence of zinc deficiency.
Extension of this line of thought would suggest that differential
levels of zinc deficiency in individuals or populations within
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attributable to zinc. Second, five meta-analyses have been
published thus far [9,16,17,18,20,21]that have all observed a
protective effect of zinc on some diarrhea outcomes, but all of
these meta-analyses have also reported a significant degree of
heterogeneity in effect sizes across studies. Such heterogeneity
raises concerns regarding the reliability of the synthetic estimates
of the use of zinc supplementation. Third, evidence is emerging
that zinc supplementation is not equally effective against all
causative organisms. [22,23] Since the causes of acute diarrhea
even within developing countries vary widely, the efficacy of zinc
supplementation is likely to be heterogeneous. Lastly, it is not clear
at present how zinc supplementation complements, if at all, other
possible options like vitamin A supplementation and multivitamin
supplementation. [23,24,25]
Together, these issues indicate the need for a closer look at the
evidence that underpins the policy of blanket zinc supplementation
to children with diarrhea in developing countries. This study
aimed to assess the therapeutic benefits of zinc supplementation in
the treatment of acute or persistent diarrhea in children, and to
examine the causes of any heterogeneity of response to zinc
supplementation.
Methods
Data Extraction
Data extraction for this study was conducted in two steps. First,
we searched the EMBASEH, CINAHLH and MEDLINEH
databases for published trials on zinc supplementation. The full
strategy for searching these databases and the results obtained are
shown in Figure 1. Second, we collected the published reviews and
meta-analyses in this field. For this, we searched the same
databases using the query ‘‘zinc AND diarrhea’’ and limiting the
citations to reviews, we identified 129 review articles of which 50
dealt with ‘‘zinc supplementation’’. Further restricting the articles
to publication type ‘‘meta-analysis’’ identified 10 articles of which
seven had formally conducted synthesis of published trials on the
preventive or the therapeutic role of zinc in acute or persistent
diarrhea. Five of these seven meta-analyses related to the
therapeutic use of zinc in diarrhea. We carefully reviewed these
five meta-analyses for any additional studies that we may have
missed in the first stage of the search (Figure 1, step 7). In total, we
identified 26 trials for acute diarrhea and 6 trials for persistent
diarrhea. Attached at the end of the manuscript are the PRISMA
statement and flowchart detailing the methods of data extraction
and abstraction.
Analytical approach
We constructed a correspondence map of the published studies
and meta-analyses to identify which studies were included in the
different meta-analyses. We then summarized the findings from
these meta-analyses into diarrhea-related clinical end-points. For
each outcome, we examined the reported summary effect sizes and
the heterogeneity across studies. For quantifying heterogeneity, we
used the I
2 statistic since it is comparable across meta-analyses.
[26] If a meta-analysis reported the Q test result for heterogeneity
then the I
2 statistic was estimated from it using the formula
I
2=(Q-df)/Q with the minimum bound set to zero.
For major outcomes that showed significant summary beneficial
effect of zinc on diarrhea, and which showed large heterogeneity
across trials, we investigated the potential contributors to the
heterogeneity. First, we conducted an updated meta-analysis to
include the results from other studies that the previous meta-
analyses may have omitted. For these meta-analyses, we used the
random effects model of DerSimonian and Laird. [27] Depending
on the diarrhea related outcome, we used standardized mean
difference or summary odds ratios as the summary measures for
effect size. For diarrhea-related outcomes showing substantial
heterogeneity across studies, we then estimated the contribution of
potential predictors of effect size to between-study heterogeneity.
For predictor variables that were categorical in nature (geographic
location and setting of the study, zinc salt used, co-intervention
used, and adequacy of blinding procedures) we used subgroup
meta-analyses. For continuous predictor variables we conducted
univariate meta-regression analyses as recommended by Higgins
et al [26] and Thomson et al [28]. Continuous variables included
in these analyses were: mean age, dose of zinc, duration of
diarrhea before admission, proportion wasted defined as weight-
for-age z score,-2, proportion stunted defined as height-for-age z
score,-2, mid-arm circumference, proportion with fever, mean
dehydration score, baseline zinc and proportion breastfed.
Statistical analyses were conducted using the Stata 10.2 (Stata
Corp, College Station, TX) software package.
Results
Systematic map of published meta-analyses on zinc
supplementation in diarrhea
In 1998, Black et al [10] conducted the first focused literature
review of zinc supplementation, which provided a significant
Figure 1. Flowchart for study selection protocol in the present
study. *, Type of diarrhea was included as acute or persistent.
doi:10.1371/journal.pone.0010386.g001
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dation [7] six years later on the use of zinc in the treatment of
childhood diarrhea. Together the published meta-analyses have
summarized data from 23 randomized controlled trials (9,958
children receiving zinc and 9,940 subjects receiving placebo)
excluding four studies [29,30,31,32] published after the meta-
analyses. For ease of identification, these meta-analyses are labeled
chronologically as M1–M5 in Table 1.
The RCTs of the therapeutic effects of zinc supplementation
during diarrhea have reported a wide variety of diarrhea-related
outcomes. For example, these RCTs report the domain of
diarrheal duration in various ways as mean duration of diarrhea
since initiation of treatment, the percentage reduction in the
duration of diarrhea, and the proportion of children with
continued diarrhea beyond a predefined number of days (1, 3, 5
or 7). In addition, other outcomes have included stool frequency,
stool output, risk of vomiting and risk of watery stools. All the five
meta-analyses [9,15,16,17,18] and most of the published random-
ized controlled trials have however, reported the effect of zinc
supplementation on mean diarrheal duration. Two meta-analyses
[9,17], report that there is about 15–16% reduction in the mean
duration of acute diarrhea while four meta-analyses [15,16,17,18]
report that zinc supplementation can reduce the acute diarrheal
duration by 0.24 to 0.67 days (Table 2). Again, for this important
outcome, the more recent meta-analyses [15,16,17,18] suggested
that the published evidence demonstrates a statistically significant
degree of heterogeneity with I
2 statistic ranging from 73% to 85%
(Table 2). Alternatively expressed, zinc supplementation appears
to reduce the risk of continued diarrhea beyond 7 days by 29%
(Table 2), although the results were heterogeneous across the
published literature (I
2.70%). On the other hand, zinc supple-
mentation does not provide a statistically significant reduction in
stool frequency or stool output and this evidence was not
heterogeneous (Table 2).
Meta-analytical synthesis of the influence of zinc supplementa-
tion is available for three more outcomes: persistent diarrhea,
vomiting after zinc administration and childhood mortality. A
smaller number of trials provide the current evidence for the
effects of zinc supplementation on persistent diarrhea compared to
acute diarrhea. Nonetheless, zinc supplementation offers a clear
benefit for persistent diarrhea and this effect was homogeneous
across the published studies (Table 3). Three meta-analyses
[16,17,18] have summarized the results from randomized
controlled trials with vomiting as an outcome, all of which found
that the risk of vomiting significantly increased after zinc
supplementation [point estimates for odds ratios (OR) ranging
from 1.22 to 1.71, Table 2]. The most recent meta-analysis
reported significant heterogeneity across study results (I
2 69%,
Table 2).
Investigation into the heterogeneity: meta-analyses and
meta-regressions
The systematic map shows that accompanying the influence of
zinc supplementation on diarrhea was heterogeneity of the results
across the published trials. We therefore conducted an investiga-
tion into the potential contributors to this heterogeneity.
Summarizing results from Tables 1 and 2, we focused our analyses
on two outcomes: mean duration of diarrhea in therapeutic trials
and the risk of vomiting in therapeutic trials. For each of these
outcomes we first implemented a random effects meta-analysis and
then undertook subgroup meta-analysis and meta-regression.
Zinc supplementation and mean diarrheal duration from
therapeutic trials. Our updated meta-analysis for this outcome
(Figure 2) showed that the published data come off 26 comparisons from
19 trials [25,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48]
representing8,957children.Weexcludedtrialsthateitherstudiedthe
effects of zinc supplementation on future episodes or did not report
the mean duration (and measures of variability) of the current
diarrheal episodes [29,49,50,51,52,53]. Our results support a
statistically significant effect of zinc supplementation on mean
diarrheal duration [standardized mean difference (SMD) 20.25,
95% CI 20.35–20.15]. Considering the statistical properties of
SMD[54], this translates into a reduction in mean diarrheal duration
by 19.7% (95% CI 11.9%–27.4%). The extent of heterogeneity
across studies was statisticallysignificant (I
286.5%, p,0.001). For this
outcome our subgroup meta-analyses (Table 4) showed that the
country of origin could not explain the heterogeneity, however age
,12 months and study setting were associated with a differential
reduction in the mean diarrheal duration. We also observed that the
beneficial effect of zinc was influenced by studies that recruited all the
study subjects before 12 months of age. We observed that in the five
study groups from two studies that recruited infants only the SMD
was 0.06 whereas when analysis was restricted to the studies that
included other age groups also the SMD was 20.32 – a difference
Table 1. Published studies therapeutic use of zinc against in
acute diarrhea.
No Author [Ref] Year Zn Pl M1 M2 M3 M4 M5
1 Sachdev et al [57] 1990 20 20 X X
2 Sazawal et al [47] 1995 456 481 X XXXX
3 Roy et al [45] 1997 37 37 X X X X
4 Hidayat et al [42] 1998 738 659 X X X X
5 Roy et al [53] 1998 95 95 X X
6 Faruque et al [39] 1999 341 340 X X X
7 D u t t a e t a l [ 3 8 ] 2 0 0 0 4 4 3 6 XXXX
8 Khatun et al [50] 2001 44 44 X
9 Strand et al [48] 2002 442 449 X X X
10 Bahl et al [34] 2002 806 401 X X X
11 Baqui et al [66] 2002 3974 4096 X
12 Al-Sonboli et al [33] 2003 37 37 XXXX
1 3 P o l a t e t a l [ 4 4 ] 2 0 0 3 9 2 9 0 XXXX
1 4 B h a t n a g a r e t a l [ 3 5 ] 2 0 0 4 1 3 2 1 3 4 XXXX
1 5 B r o o k s e t a l [ 3 7 ] 2 0 0 5 1 7 1 8 9 XXXX
16 Larson et al [67] 2005 534 533 X X
17 Patel et al [43] 2005 102 98 X X
18 Valery et al [25] 2005 107 108 X
19 Fischer Walker et al
[40]
2 0 0 6 5 3 8 5 3 6 XXXX
20 Awasthi et al [49] 2006 1010 992 X
21 Boran et al [36] 2006 150 130 X X
22 Roy et al [52] 2007 28 28 X X
23 Gregorio et al [41] 2007 60 57 X X
24 Roy et al [32] 2008 82 82 X
25 Patel et al [31] 2009 535 273
26 Fijolu et al [29] 2009 30 30
X indicates that the trial was included in the specified meta-analysis.
M1, Bhutta et al 2000 [9]; M2, Lukacik et al 2008 [17]; M3, Patro et al 2008 [18];
M4, Lazzerini et al 2008 [16]; M5, Haider and Bhutta [15].
Zn, Lumber of subjects in the Zn supplementation Group; Pl, Number of
subjects in the placebo Group.
doi:10.1371/journal.pone.0010386.t001
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Outcome Meta-analysis RCTs N Statistic ES 95% CI I
2 (%), p
Recovery from diarrhea M1 3 2446 RH 0.85* 0.76–0.95 65, 0.04
Diarrhea at day 1 M2 5 3100 RR 1.01 0.99–1.03 63, 0.03
Diarrhea at day 3 M2 6 3908 RR 0.97 0.91–1.03 55, 0.05
M3 3 1630 RR 0.62* 0.44–0.87 ---
M4 3 1073 RR 0.69* 0.59–0.81 48, 0.116
Diarrhea at day 5 M2 6 3908 RR 0.94 0.84–1.05 74, 0.002
M3 2 346 RR 0.68 0.11–4.31 ---
M4 2 346 RR 0.55* 0.32–0.95 43, 0.19
Diarrhea for $7 days M1 3 289 OR 0.78 0.56–1.09 0, 0.71
M3 8 5769 RR 0.71* 0.53–0.96 ---
M4 10 4087 RR 0.71* 0.52–0.98 73, 0.0001
Duration of diarrhea M1 5 3177 % Q 16.2* 6.8–25.6 0, 0.56
M2 16 15272 % Q 15.0 --- 84, 7.5610
214
M2 16 15272 WMD, d 0.24* 0.21–0.27 84.3, 8.9610
214
M3 13 5643 WMD, d 20.69* 20.97–20.40 73, 1.6610
26
M4 13 2741 WMD, h 212.27* 223.02–21.52 85, 1.8610
211
M5 14 5670 WMD, d 20.50* 20.82–20.08 84, 4.1610
212
Stool frequency M2 7 3117 % Q 18.0 --- ---
M3 3 1384 WMD 20.02 20.29–0.25 ---
M4 7 1458 WMD 20.02 20.19–0.15 53, 0.05
Stool output M2 3 478 % Q 30.3 --- ---
M3 3 606 WMD 20.38 21.04–0.27 ---
Vomiting M2 11 4438 RR 1.55* 1.30–1.84 60.8, 0.004
M3 5 3156 RR 1.22* 1.05–1.43 ---
M4 10 4727 RR 1.71* 1.27–2.30 69.3, 0.001
Watery stools M3 3 3476 RR 0.86* 0.77–0.97 ---
M1, Bhutta et al 2000 [9]; M2, Lukacik et al 2008 [17]; M3, Patro et al 2008 [18]; M4, Lazzerini et al 2008 [16]; M5, Haider and Bhutta [15].
OR, odds ratio; RR, relative risk; RH, relative hazards; WMD, weighted mean difference; RCT, Lumber of randomized control trials used; N, Number of subjects included in
meta-analysis; ES, summary effect size, CI, confidence interval; d, days; h, hours; % Q, percentage reduction.
M1 reported Q statistic and degrees of freedom and the I
2 statstic was derived using the formula I
2=(Q-df)/Q. *, statistically significant; ---, not mentioned and not
estimable.
doi:10.1371/journal.pone.0010386.t002
Table 3. Outcomes and summary effects related to persistent diarrhea observed in published meta-analyses.
Outcome Meta-analysis RCTs N Statistic ES 95% CI I
2 (%), p
Recovery from persistent diarrhea M1 4 680 RH 0.76* 0.63–0.91 ---
Occurrence of diarrhea at day 1 M2 2 221 RR 1.00 0.93–1.08 0, 0.93
Occurrence of diarrhea at day 3 M2 2 221 RR 0.70* 0.51–0.94 0, 0.56
Continuation of diarrhea .7 days M1 4 680 RR 0.61 0.26–1.46 ---
Duration of persistent diarrhea M1 4 680 % Q 29.3* 6.0–52.5 0, 0.559
M2 5 489 % Q 15.5 --- ---
M2 5 489 WMD, d 0.299* 0.120–0.478 29.9, 0.544
Vomiting
M2 4 2969 RR 3.64* 1.02–13.02 49.2, 0.116
M1, Bhutta et al 2000 [9]; M2, Lukacik et al 2008 [17].
OR, odds ratio; RR, relative risk; RH, relative hazards; WMD, weighted mean difference; RCT, Lumber of randomized control trials used; N, Number of subjects included in
meta-analysis; ES, summary effect size, CI, confidence interval; d, days; % Q, percentage reduction.
M1 reported Q statistic and degrees of freedom and the I
2 statstic was derived using the formula I
2=(Q-df)/Q. *, statistically significant; ---, not mentioned and not
estimable.
doi:10.1371/journal.pone.0010386.t003
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p-value for difference in SMDs=0.006). The hospital-based studies
[25,31,32,33,35,37,38,39,43,45,46] were more likely to show
improvement as compared to studies conducted in community
settings [34,40,41,42,47,48] (SMD 20.33 versus 20.13, respectively
and unpaired Student’s t test p value=0.049). Studies using zinc
gluconate [34,47,48] and those using vitamin A as a co-intervention
[25,39,48] showed a significant reduction in diarrheal duration and
were homogeneous (Table 4).
We also explored the effect of causative organisms. Seven trials
[31,32,33,35,38,45,46] have reported the array of causative
organisms for diarrhea and in the present review we observed that
the effect of zinc on mean diarrheal duration was significant in trials
not reporting Esherichia coli and rotavirus as the causes (SMD 20.14,
95% CI20.21–20.07; data not shown). Finally, results of our meta-
regressionanalysesshowed(Figure3aandc)thatthedoseofzincwas
the only variable that was statistically significantly associated with
diarrheal duration – trials using higher doses generally reported
larger effect of zinc supplementation on mean diarrheal duration
(p=0.02). Interestingly, average baseline zinc levels did not
contribute to between-study variations in the effect size (p=0.70)
Zinc supplementation and risk of vomiting. Rates of
vomiting after zinc administration have been reported in 14
comparisons from 10 trials [25,34,35,36,37,40,44,46,47,48]
representing 6,779 children. In a quantitative synthesis of these
results (Figure 4), we observed that the risk of vomiting was
significantly increased after zinc administration (19.2% in the zinc
supplementedgroupand9.2%inthezincwithheldgroup)summary
OR 2.13, 95% CI 1.37–3.31). However, this zinc effect was
significantly heterogeneously distributed across the trials (I
2 81.2%,
p,0.001).
In the subgroup analyses (Table 4) we found that studies from
India [34,35,40,47], studies using zinc acetate [37], those using
multivitamins as a co-intervention [35,47], and those in which the
efficiency of the blinding procedure was unclear [25,36,44] were
homogeneous in terms of the reported associations. Of these
subgroups, the studies from India, studies using zinc acetate and
those using multivitamins did not show a significant association of
zinc supplementation with vomiting. The strongest association
with vomiting was found in studies [34,36,37,40,44,48] that used
no co-intervention in addition to zinc (OR 2.55, 95% CI 1.40–
4.63). In addition, well-blinded studies [34,35,37,40,47,48], those
studies conducted in hospital settings [25,35,37] and studies using
zinc gluconate [34,47,48] reported a high degree of association
between zinc supplementation and the risk of vomiting. In meta-
regression analyses (Figure 3b and d), we observed that the
Figure 2. Forest plot depicting the studies included in our meta-analysis for the outcome of mean diarrheal duration. Orange squares
and lines indicate the point and 95% confidence intervals for the standardized mean deviations (SMD) and the orange diamond denotes the point
and confidence interval for the summary effect size. Suffixes a, b and c indicate specific zinc-treated subgroups within the indicated study. Weights
are expressed in percentage.
doi:10.1371/journal.pone.0010386.g002
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p=0.005), the proportion of the children who were stunted (8
comparison groups, p=0.027) and the proportion of children
who were breastfed (6 comparison groups, p=0.006) were the
variables that were significantly associated with the reported
rates of vomiting. Since the inference for the association of
pre-admission diarrheal duration with vomiting came from
almost all the studies included in this meta-regression, we
specifically examined this association. The I
2 statistic after
accounting for pre-admission diarrheal duration shrunk from
81.2% to 48.1% indicating that a large proportion of the
variability across trials could be explained by the duration of
pre-admission diarrhea.
Influence of zinc supplementation on persistent diarrhea
Table 3 demonstrates that zinc supplementation has a clear
benefit in reducing the incidence of persistent diarrhea by
approximately 25%. It improved the recovery from persistent
diarrhea by 24% and reduced the proportion of children with
persistent diarrhea extending beyond three days after zinc
supplementation by 30%. It also reduced the mean duration of
persistent diarrhea by 21.5–29.3%, although it was associated with
a significantly high risk of vomiting. For all these outcomes, the
existing evidence demonstrates a high degree of homogeneity of
effects across the published trials. The most recent meta-analysis
[16] reported on five trials in children with persistent diarrhea
[50,53,55,56,57]. Three trials reported on diarrhea at day three
[44,48,56], three trials on diarrhea at day five [35,38,56] and nine
at day seven [35,39,40,44,47,48,50,52,56]. There was a reduction
in persistent diarrhea by 215.84% [95% CI 225.43–26.24%].
As no new trials on influence of zinc on outcomes of persistent
diarrhea have been published since the publication of these meta-
analyses, we did not conduct a redundant synthetic investigation
into this effect of zinc. Also, due to the small number of trials we
did not conduct subgroup analyses or meta-regression for the
outcome of persistent diarrhea.
Table 4. Results of subgroup meta-analyses for the outcomes of mean diarrheal duration and risk of vomiting.
Variable/Category Duration Vomiting
SG* SMD 95% CI I
2 SG* OR 95% CI I
2
Location
India 10 20.23 20.42–20.03 89.6 5 1.19 0.87–1.64 43.0
Bangladesh 5 20.44 20.89–0.02 92.8 2 2.18 0.91–5.22 0.0
Indonesia 1 20.12 20.20–20.04 ---
Nepal 3 20.21 20.28–20.13 0.0 3 4.23 3.26–5.49 0.0
Brazil 1 20.93 21.41–20.45 ---
Turkey 2 20.44 20.84–20.04 77.5 2 6.18 1.92–19.9 0.0
Australia 1 20.01 20.20–0.18 --- 1 0.51 0.05–5.71 ---
Pakistan 1 0.07 20.09–0.24 ---
Ethiopia 1 20.10 20.39–0.20 ---
Philippines 1 20.52 20.89–20.15 ---
Age $12m
Yes 21 0.06 20.04–0.16 0.0 10 2.23 1.29–3.85 85.2
No 5 20.32 20.44–20.21 87.7 3 1.59 1.37–3.31 0.0
Setting
Hospital 13 20.42 20.67–20.18 91.6 4 1.19 0.65–2.20 24.1
Community 11 20.13 20.20–0.05 65.7 7 2.26 1.33–3.84 87.0
Unclear 2 20.44 20.84–20.04 77.5 2 6.18 1.92–19.9 0.00
Zinc salt
Acetate 6 20.35 20.64–20.07 91.5 2 2.18 0.91–5.22 0.0
Gluconate 6 20.18 20.24–20.11 30.0 6 2.44 1.33–4.47 88.0
Sulfate 14 20.31 20.51–20.11 88.8 5 1.58 0.78–3.21 61.4
Co-intervention
None 14 20.16 20.26–20.07 72.5 8 2.55 1.40–4.63 82.8
Vitamin A 3 20.15 20.25–20.05 21.1 2 2.07 0.30–14.4 64.3
Multivitamins 2 21.01 22.59–0.58 97.5 2 0.87 0.52–1.44 0.0
Erythromycin 1 20.33 20.64–20.02 ---
ORS 6 20.43 20.79–20.08 93.5 1 1.74 1.14–2.66 ---
Efficient blinding
Yes 17 20.24 20.36–20.15 89.0 9 2.01 1.26–3.21 84.8
Unclear 7 20.29 20.51–0.07 75.2 3 3.28 0.67–16.1 42.0
*, Number of study groups included in meta-analysis.
doi:10.1371/journal.pone.0010386.t004
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The results of our systematic review suggest that zinc
supplementation reduced the mean duration of acute diarrhea
by approximately 20%, and persistent diarrhea by 15–30%, but
had no significant effect on stool frequency or stool output. Further
it was associated with a two- to three-fold higher risk of
regurgitation in acute and persistent diarrhea, respectively. There
was a high degree of statistically significant heterogeneity across
the published studies for the effects of zinc supplementation on
mean diarrheal duration and risk of vomiting following the
administration of zinc.
Consistent with the existing understanding [15,58], the
therapeutic trials showed that zinc would reduce diarrhea by
nearly a day for an average episode of five days, but again there
was a high degree of heterogeneity of this effect across the
published studies. The World Health Organization (WHO)
recommends zinc supplementation (10–20mg for 10–14 days) for
treatment of acute diarrhea. [7] Although the recommendation
does not specify the salt, our subgroup analysis showed a
significant homogeneous reduction in diarrheal duration in studies
using zinc gluconate [34,48] and those using vitamin A as a co-
intervention [25,39,48] (Table 4). Vitamin A supplementation up-
regulates the Th2 immune response, while zinc supplementation
up regulates Th1 responses, and perhaps these interventions have
synergistic effects, a research question which needs further
exploration. [23]
Interestingly, higher doses of zinc in the therapeutic trials were
associated with larger reductions in the mean duration of diarrhea.
It is difficult to comment on the potential relationship between
zinc dose and diarrheal duration in the context of achieving a
balance between the reduction of diarrhea and risk of vomiting. If
similar benefits of treatment are possible with lower doses and
there is a lower risk of vomiting with these doses then lower doses
Figure 3. Investigation of the potential contribution of continuous variables to heterogeneity across study results for the outcomes
of mean diarrheal duration and risk of vomiting. (A and B) Results from univariate meta-regression for continuous variables as predictors of
the between-study heterogeneity for mean diarrheal duration (A) and risk of vomiting (B). The statistical significance is shown as log transformed p-
value and the vertical dashed line corresponds to a p-value of 0.05. Blue dots, statistically insignificant; red dot, statistically significant. (C and D)
Bubble plots showing the influence of the dose of elemental zinc as a predictor of the standardized mean difference of diarrheal duration (C) and log
odds ratio of the risk of vomiting (D). Each bubble represents a study group listed in Figure 2 and the size of the bubble is proportional to the inverse-
variance weights.
doi:10.1371/journal.pone.0010386.g003
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question would therefore be more appropriate. Similarly, the fact
that subgroup analysis but not meta-regression demonstrated a
differential benefit of zinc supplementation indicates that there
may be a threshold for age beyond which zinc supplementation
may be useful. However, the lack of an association between mean
age in a trial and the effect of zinc may also reflect a lack of
informative content in mean age as a contributor to heterogeneity
and thus trials focused to address these issues would be
appropriate.
An important finding from our analyses was that zinc
supplementation showed no effect on stool frequency and output.
This opens up the possibility that care-givers may not perceive a
beneficial impact of treating their children with zinc, which might
negatively affect their adherence to the treatment regime. Another
potential barrier to treatment adherence with zinc supplements
was the significantly increased risk of vomiting. These findings
imply that use of zinc supplements is unlikely to improve
compliance with the treatment for diarrheal disease. It is
noteworthy however, that a recent study of the safety of zinc
supplementation in acute diarrhea suggests that most of the
patients regurgitate only once – a phenomenon that may not affect
the continuation of zinc therapy. [59] Further, in our subgroup
analyses, compared to zinc acetate, zinc gluconate was signifi-
cantly associated with a reduction in the duration of diarrhea but
also showed a significantly increased risk of vomiting. These
findings highlight the imbroglio facing those designing an
intervention program - which salt should be used, at what dose,
frequency, and duration, to maximize the acceptance and benefits
of zinc supplementation as an adjunct in the treatment of
childhood diarrhea. Moreover, the fact that zinc supplementation
was beneficial in the absence of E. coli and rotavirus calls for a
closer look into the clinical and public health scenarios where this
intervention may be most beneficial. Whether such a strategy of
zinc supplementation that is tiered on the basis of the causative
organism will be efficacious and effective is currently unknown.
The WHO recommendations do not fully address these issues and
protocols for the use of zinc in diarrhea treatment programs need
revisiting.
Stunted children are likely to be zinc deficient and therefore
should benefit from zinc supplementation [60,61]. Our analysis
surprisingly showed that factors such as age, malnutrition
(proportion stunted and wasted), breast feeding, dehydration at
enrolment and baseline zinc, which have previously been reported
to affect the response to zinc for reducing duration of diarrhea, did
not show a statistically significant effect. It should be noted,
however, that the baseline plasma zinc concentrations reported in
trials may not fully capture the state of zinc deficiency in the
children. Such values are likely confounded by acute phase
response, diurnal variations and time since previous meals
[62,63,64]. Therefore, our observed lack of an association between
baseline plasma concentration and zinc efficacy should be
cautiously interpreted. On the other hand diarrheal duration
before admission, stunting, wasting, and being breast fed were
factors significantly associated with the reported rates of vomiting
following supplementation with zinc. Thus, the population most
likely to benefit from zinc supplementation was also the population
at an increased risk of vomiting.
Figure 4. Forest plot depicting the studies included in our meta-analysis for the outcome of risk of vomiting. Red squares and lines
indicate the point and 95% confidence intervals for the odds ratios (OR) and the red diamond denotes the point and confidence interval for the
summary effect size. Suffixes a, b and c indicate specific zinc-treated subgroups within the indicated study. Weights are expressed in percentage.
doi:10.1371/journal.pone.0010386.g004
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inherent limitations. For example, because only a few studies
reported information on most of the predictor variables simulta-
neously, we could not conduct multivariate meta-regression
analyses. Thus, the importance of the factors that we identified
is unknown in a multivariate context. In addition, even though
meta-regression can provide important clues into the potential
contributors to the summary effect size [65], it can only examine
those covariates reported in the trials examined. Only eight trials
[24,31,32,33,34,38,45,46] have reported as covariates, diarrheal
etiology or causative organisms as covariates. In the present review
we observed that the effect of zinc on mean diarrheal duration was
significant in trials where Esherichia coli and rotavirus were not
causes of the diarrhea (SMD 20.14, 95% CI 20.21–20.07). The
role of other unknown covariates like adherence and acceptability
remains unknown. Indeed, we did observe that significant
heterogeneity across study results remained even after accounting
for the potential predictors of between-study heterogeneity. Lastly,
subgroup analyses and meta-regression are, by disposition,
exploratory tools to provide pointers towards possible sources of
heterogeneity - they cannot be taken as confirmatory tests for
definitive conclusions and interpretations about the causes of
heterogeneity.
Our findings for the use of zinc in the treatment of diarrhea
indicate the need to improve upon the current strategy of zinc
supplementation for all children with diarrhea, by selecting the
populations most likely to benefit from supplementation and using
the most effective zinc salt. There is a need to optimize the use of
zinc supplementation in childhood diarrheas and this will require
further investigation of the factors leading to the heterogeneity of
the effects of zinc as an adjunct in its treatment.
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